Search

Your search keyword '"Advaxis Inc. -- Intellectual property"' showing total 54 results
Start Over Descriptor "Advaxis Inc. -- Intellectual property"
54 results on '"Advaxis Inc. -- Intellectual property"'

1. 'Immunogenic Compositions Targeting Recurrent Cancer Mutations And Methods Of Use Thereof' in Patent Application Approval Process (USPTO 20240124540)

Subjects
Advaxis Inc. -- Intellectual property, Diseases -- Relapse, Biotechnology industry -- Intellectual property, Vaccines -- Intellectual property -- Methods, Health
Abstract

2024 MAY 8 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A patent application by the inventors Balli, David (Warrington, PA, US); Coder, Brandon (Trenton, NJ, [...]

Published
2024

2. Patent Issued for Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof (USPTO 11897927)

Subjects
Advaxis Inc. -- Intellectual property, Listeria -- Methods, Diseases -- Relapse, Biotechnology industry -- Intellectual property, Amino acids -- Intellectual property -- Methods -- Genetic aspects, Vaccines -- Intellectual property -- Methods, Health
Abstract

2024 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Advaxis Inc. (Princeton, New Jersey, United States) has been issued patent number 11897927, according to [...]

Published
2024

3. Patent Issued for Compositions and methods comprising KLK3 or FOLH1 antigen (USPTO 11446369)

Subjects
Advaxis Inc. -- Intellectual property, BCG vaccines -- Intellectual property -- Methods, Listeria -- Methods, Prostate-specific antigen -- Methods, BCG -- Intellectual property -- Methods, Biotechnology industry -- Intellectual property, Kallikrein -- Methods, Business, Health, Health care industry
Abstract

2022 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- A patent by the inventors Paterson, Yvonne (Philadelphia, PA, US), Rothman, John (Lebanon, NJ, US), [...]

Published
2022

4. Patent Application Titled 'Compositions And Methods For Lyophilization Of Bacteria Or Listeria Strains' Published Online (USPTO 20220062181)

Subjects
Advaxis Inc. -- Intellectual property, Listeria -- Methods, Biotechnology industry -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2022 MAR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2022

6. 'Compositions And Methods For Evaluating Potency Of Listeria-Based Immunotherapeutics' in Patent Application Approval Process (USPTO 20210239681)

Subjects
Advaxis Inc. -- Intellectual property, Listeria -- Methods, Biotechnology industry -- Intellectual property, Biotechnology industry, Biological sciences, Business
Abstract

2021 AUG 23 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- A patent application by the inventors GRACE, Mike (Princeton, NJ, US); WALLECHA, Anu (Yardley, [...]

Published
2021

7. 'Immunogenic Heteroclitic Peptides From Cancer-Associated Proteins And Methods Of Use Thereof' in Patent Application Approval Process (USPTO 20210177955)

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Amino acids -- Methods -- Intellectual property, Cancer -- Methods, Vaccines -- Intellectual property -- Methods, Peptides -- Methods, Health
Abstract

2021 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A patent application by the inventors BALLI, David (Warrington, PA, US); CODER, Brandon (Trenton, NJ, [...]

Published
2021

8. Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac

Subjects
United States. Food and Drug Administration, Advaxis Inc. -- Intellectual property, Biotechnology industries -- Intellectual property, Biological products, Immunotherapy, Cervical cancer, Patents, Trademarks, Cancer, Intellectual property, Proteins, Patent/copyright issue, Business, Business, international
Abstract

Currently in a Phase 3 Pivotal Study for High-Risk Locally Advanced Cervical Cancer PRINCETON, N.J. -- Advaxis, Inc. (NASDAQ: ADXS) (the Company),a late-stage biotechnology company focused on the discovery, development [...]

Published
2019

9. Advaxis Granted US Patent Relating to Axalimogene Filolisbac

Subjects
United States. Food and Drug Administration, Advaxis Inc. -- Intellectual property, Biotechnology industries -- Intellectual property, Biological products, T cells, Immunotherapy, Papillomavirus infections, Bacteria, Listeria, Cancer, Antigens, Tumors, Proteins, Chemistry
Abstract

M2 PHARMA-March 26, 2019-Advaxis Granted US Patent Relating to Axalimogene Filolisbac (C)2019 M2 COMMUNICATIONS - US-based biotechnology company Advaxis, Inc. (NASDAQ: ADXS) has granted patent number 10,189,885 titled 'Non-Hemolytic LLO [...]

Published
2019

10. U.S. Patent and Trademark Office Approves Patent Application That Extends Advaxis Technology to Include HER2/neu for Use in Listeria and Proten Vaccines

Subjects
Advaxis Inc. -- Intellectual property, Listeriosis, Trademarks, Biotechnology industry -- Intellectual property, Immunotherapy, Antigens, Patents, Cancer vaccines -- Contamination, Patent/copyright issue, Health
Abstract

The U.S. Patent and Trademark Office has approved Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, [...]

Published
2010

11. U.S. Patent and Trademark Office Issues Patent for Live Listeria HER2/neu Immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Health, Listeriosis, Trademarks, Biotechnology industry -- Intellectual property, Immunotherapy, Patents, Cancer vaccines, Patent/copyright issue, Health
Abstract

The U.S. Patent and Trademark Office has issued to Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled 'Methods and Compositions for Immunotherapy [...]

Published
2010

12. U.S. Patent & Trademark Office to Allow for New Advaxis Patent

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Antigens, Vaccines, Patents, Patent/copyright issue, Health
Abstract

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its [...]

Published
2010

13. Advaxis Expands Intellectual Property for Lm Technology Platform

Subjects
Advaxis Inc. -- Intellectual property, Tumor antigens, Intellectual property, Biotechnology industries -- Intellectual property, Immunotherapy, Intellectual property, Telecommunications industry
Abstract

(GlobeNewswire) - Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it has added two more patents to its growing patent portfolio. The first patent, [...]

Published
2016

14. Advaxis Expands Intellectual Property for Lm Technology(TM) Platform

Subjects
Advaxis Inc. -- Intellectual property, Tumor antigens, Intellectual property, Biotechnology industries -- Intellectual property, Immunotherapy, Intellectual property, Banking, finance and accounting industries, Business
Abstract

PRINCETON, N.J., Jan 19, 2016 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it has added two more patents [...]

Published
2016

15. Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industries -- Intellectual property, Immunotherapy, Telecommunications industry
Abstract

(GlobeNewswire) - Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,084,747 with [...]

Published
2015

16. Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industries -- Intellectual property, Immunotherapy, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Jul 21, 2015 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) [...]

Published
2015

17. Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property Portfolio With Two USPTO Patents Addressing ADXS-PSA and ADXS-HER2

Subjects
Merck & Company Inc. -- Intellectual property, Advaxis Inc. -- Intellectual property, Cancer treatment, Intellectual property, Cancer, Prostate specific antigen, Biotechnology industries -- Intellectual property, Immunotherapy, Pharmaceutical industry -- Intellectual property, Intellectual property, Real estate industry
Abstract

(GlobeNewswire) - Advaxis, Inc. (Nasdaq:ADXS), a cancer immunotherapy company, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,012,141 with composition of matter [...]

Published
2015

18. Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property Portfolio With Two USPTO Patents Addressing ADXS-PSA and ADXS-HER2

Subjects
Merck & Company Inc. -- Intellectual property, Advaxis Inc. -- Intellectual property, Cancer treatment, Intellectual property, Cancer, Prostate specific antigen, Biotechnology industries -- Intellectual property, Immunotherapy, Pharmaceutical industry -- Intellectual property, Intellectual property, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Apr 28, 2015 (GLOBE NEWSWIRE via COMTEX) -- ADXS-PSA Patent Covers a Recombinant Listeria Strain Encoded with Recombinant Fusion Peptide of KLK3 Peptide Linked to Non-KLK3 Peptide ADXS-HER2 Patent [...]

Published
2015

19. Advaxis Receives Notice of Allowance for Cancer Immunotherapies Patent in Japan

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Patents, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Jul 28, 2014 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has received a notice of [...]

Published
2014

20. Advaxis Receives Notice of Allowance From U.S. Patent Office for Two Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2

Subjects
Advaxis Inc. -- Intellectual property, Orphan drugs, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Stomach cancer, Patents, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Jun 23, 2014 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has received notice of allowance from the United States Patent and [...]

Published
2014

21. Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Patents, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Apr 14, 2014 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to [...]

Published
2014

22. Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Patents, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

PRINCETON, Apr 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark [...]

Published
2014

23. Aduro BioTech Patent Upheld by USPTO

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology, Biotechnology industry -- Intellectual property, Patents, Patent infringement, Patent/copyright issue, Business, Business, international
Abstract

BERKELEY, Calif. -- Aduro BioTech, Inc. announces that the United States Patent and Trademark Office (USPTO) has confirmed the patentability of its U.S. Patent 7,842,289 ('289 patent) at the successful [...]

Published
2011

24. Advaxis Inc receives US Notice of Allowance for patent for ADXS-HPV

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Cervical cancer, Patents, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Oct 19, 2011 (M2 EQUITYBITES via COMTEX) -- Biotechnology company Advaxis Inc (OTCBB:ADXS.ob) reported on Tuesday the receipt of a Notice of Allowance for a US Patent titled 'Compositions and [...]

Published
2011

25. Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV Immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Metastasis, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Cervical cancer, Patents, Patent/copyright issue, Business, Business, international
Abstract

PRINCETON, N.J. -- Advaxis, Inc ., (OTCBB: ADXS) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that the United States Patent [...]

Published
2011

26. Advaxis gets US patent for live Listeria HER2/NEU immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Patents, Patent/copyright issue, Business, Chemicals, plastics and rubber industries
Abstract

Advaxis Inc has obtained a US patent for its live attenuated Listeria monocytogenes [...]

Published
2010

27. Advaxis Inc receives US patent for live Listeria HER2/neu immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Patents, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Sep 10, 2010 (M2 EQUITYBITES via COMTEX) -- Biotechnology company Advaxis Inc (OTCBB: ADXS) reported on Thursday that it has been granted US patent number 7,784,729 titled aEURoeMethods and Compositions [...]

Published
2010

28. US Patent and Trademark Office issues patent for live Listeria HER2/neu immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Immunotherapy, Patents, Cancer vaccines, Patent/copyright issue, Business, Chemicals, plastics and rubber industries
Abstract

The US Patent and Trademark Office has issued to Advaxis Inc, patent number 7,784,729 titled 'Methods and Compositions for Immunotherapy of Cancer,' based upon patent application 10/949,667. This patent extends [...]

Published
2010

29. U.S. Patent and Trademark Office Issues Patent for Live Listeria HER2/neu Immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Immunotherapy, Cancer -- Care and treatment, Patents, Cancer vaccines, Patent/copyright issue, Business, Business, international
Abstract

ADXS31-164 to Be Used in Multiple Cancer Indications NORTH BRUNSWICK, N.J. -- The U.S. Patent and Trademark Office has issued to Advaxis, Inc ., (OTCBB: ADXS) , the live, attenuated [...]

Published
2010

30. US Patent and Trademark Office approves patent application that extends Advaxis Technology to include HER2/neu for use in listeria and proten vaccines

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Antigens, Patents, Cancer vaccines -- Contamination, Patent/copyright issue, Business, Chemicals, plastics and rubber industries
Abstract

The US Patent and Trademark Office has approved Advaxis Inc, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria [...]

Published
2010

31. European patent office allows Advaxis/U Penn modified LLO patent

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Antigens, Patents, Patent/copyright issue, Business, Chemicals, plastics and rubber industries
Abstract

Advaxis Inc, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for [...]

Published
2010

32. Advaxis Inc to receive new vaccine technology patent from USPTO

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Vaccines, Patents, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Aug 23, 2010 (M2 EQUITYBITES via COMTEX) -- Biotechnology company Advaxis Inc (OTCBB:ADXS) said on Friday that it has received notification that the US Patent and Trademark Office (USPTO) will [...]

Published
2010

33. U.S. Patent & Trademark Office to Allow for New Advaxis Patent

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Vaccines, Patents, Patent/copyright issue, Business, Business, international
Abstract

'Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same' (Application No. 11/785,249) Patent To Extent Protection of Listeria -based Vaccine Technology Platform NORTH BRUNSWICK, N.J. -- Advaxis, Inc [...]

Published
2010

34. US Patent & Trademark Office to allow for new Advaxis patent

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Vaccines, Patents, Patent/copyright issue, Business, Chemicals, plastics and rubber industries
Abstract

Advaxis Inc has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No 11/785,249 entitled, Antibiotic Resistance Free Vaccines and Methods [...]

Published
2010

35. USPTO Grants Advaxis New Listeria Based Fusion Protein Patent

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Antigens, Cancer -- Care and treatment, Proteins, Patents, Patent/copyright issue, Business, Business, international
Abstract

Protein Family Effective in Treating Cancer in Presence of Immune Tolerance NORTH BRUNSWICK, N.J. -- The US Patent and Trademark Office (USPTO) has issued Advaxis, Inc., (OTCBB: ADXS), the live, [...]

Published
2010

36. Advaxis Issued New Intellectual Property Patent

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Antigens, Cancer -- Care and treatment, Intellectual property, Business, Business, international, University of Pennsylvania
Abstract

NORTH BRUNSWICK, N.J. -- The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, 'Compositions and Methods for Enhancing the Immunogenicity of Antigens,' by Dr. Yvonne Paterson, et al, [...]

Published
2010

37. Advaxis Granted New Compositions and Methods Patent

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Methods, Patent/copyright issue, Cancer treatment -- Methods, Antigens -- Methods, Patents -- Methods, Biotechnology industries -- Intellectual property -- Methods, Biological products -- Methods -- Intellectual property, Proteins -- Methods, Biological products industry -- Intellectual property -- Methods, Biotechnology industry -- Intellectual property -- Methods, Cancer -- Care and treatment
Abstract

New Family of Antigen-Adjuvant Fusion Proteins: Patent No. 7,588,930 NORTH BRUNSWICK, N.J. -- Please replace the release dated Sept. 21, 2009 with the following corrected version due to multiple revisions. [...]

Published
2009

38. Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights

Subjects
Advaxis Inc. -- Intellectual property, Trademarks, Biotechnology industry -- Intellectual property, Antigens, Cancer -- Care and treatment, Clinical trials, Patents, Proteins, Patent/copyright issue, Business, Business, international
Abstract

Compositions and Methods for Enhancing Immunogenicity of Antigens NORTH BRUNSWICK, N.J. -- The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the [...]

Published
2009

39. New Intellectual Property Patent for Advaxis Issued

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Cancer -- Care and treatment, Intellectual property, Business, Business, international, University of Pennsylvania -- Intellectual property
Abstract

U.S. Patent and Trademark Office Assigned Patent Number 7,488,487 To The Trustees of the University Of Pennsylvania and Licensed To Advaxis NORTH BRUNSWICK, N.J. -- The U.S. Patent and Trademark [...]

Published
2009

40. Aduro BioTech Patent Upheld by USPTO

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology, Biotechnology industry -- Intellectual property, Cancer -- Care and treatment, Patents, Cancer vaccines, Patent infringement, Patent/copyright issue, Health
Abstract

Aduro BioTech, Inc. announces that the United States Patent and Trademark Office (USPTO) has confirmed the patentability of its U.S. Patent 7,842,289 ('289 patent) at the successful conclusion of an [...]

Published
2011

41. Advaxis Inc receives US Notice of Allowance for patent for ADXS-HPV

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Cervical cancer, Patents, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-October 19, 2011-Advaxis Inc receives US Notice of Allowance for patent for ADXS-HPV(C)2011 M2 COMMUNICATIONS http://www.m2.com Biotechnology company Advaxis Inc (OTCBB:ADXS.ob) reported on Tuesday the receipt of a Notice [...]

Published
2011

42. Advaxis Inc receives US patent for live Listeria HER2/neu immunotherapy

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Immunotherapy, Patents, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-September 10, 2010-Advaxis Inc receives US patent for live Listeria HER2/neu immunotherapy(C)2010 M2 COMMUNICATIONS http://www.m2.com Biotechnology company Advaxis Inc (OTCBB: ADXS) reported on Thursday that it has been granted [...]

Published
2010

43. European Patent Office Allows Advaxis/U. Penn Modified LLO Patent

Subjects
Advaxis Inc. -- Intellectual property, Communicable diseases, Biological products, Biotechnology industry -- Intellectual property, Antigens, Patents, Proteins, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology, University of Pennsylvania
Abstract

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like [...]

Published
2010

44. Advaxis Inc to receive new vaccine technology patent from USPTO

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Vaccines, Patents, Patent/copyright issue, Business
Abstract

M2 EQUITYBITES-23 August 2010-Advaxis Inc to receive new vaccine technology patent from USPTO(C)2010 M2 COMMUNICATIONS http://www.m2.com Biotechnology company Advaxis Inc (OTCBB:ADXS) said on Friday that it has received notification that [...]

Published
2010

45. USPTO Grants Advaxis New Listeria Based Fusion Protein Patent

Subjects
Advaxis Inc. -- Intellectual property, Biological products, Biotechnology industry -- Intellectual property, Immunotherapy, Drugs, Cancer, Proteins, Patents, Patent/copyright issue, Health
Abstract

The US Patent and Trademark Office (USPTO) has issued Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent #7662396 titled 'Compositions and Methods for Enhancing the [...]

Published
2010

46. Advaxis Issued New Intellectual Property Patent

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Drugs, Antigens, Cancer -- Care and treatment, Intellectual property, Pharmaceuticals and cosmetics industries, Health, Science and technology, University of Pennsylvania
Abstract

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, 'Compositions and Methods for Enhancing the Immunogenicity of Antigens,' by Dr. Yvonne Paterson, et al, which is assigned to [...]

Published
2010

47. Advaxis Secures New Intellectual Property Patent

Subjects
Advaxis Inc. -- Intellectual property, Intellectual property, Biotechnology industry -- Intellectual property, Intellectual property, Business, Business, international, Telecommunications industry
Abstract

The U.S. Patent and Trademark Office (USPTO) has issued patent 7,635,479, 'Compositions and Methods for Enhancing the Immunogenicity of Antigens,' by Dr. Yvonne Paterson, et al, which is assigned to [...]

Published
2010

48. Advaxis Secures European Patent for New Listeria Vector

Subjects
Advaxis Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Vaccines, Patents, Patent/copyright issue, Business, Business, international, Telecommunications industry
Abstract

Advaxis, Inc. said that it has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled 'Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous [...]

Published
2010

49. Advaxis Granted New Compositions and Methods Patent

Subjects
Advaxis Inc. -- Intellectual property, Biological products industry -- Intellectual property -- Methods, Communicable diseases -- Methods, Biotechnology industry -- Intellectual property -- Methods, Immunotherapy -- Methods, Antigens -- Methods, Cancer -- Care and treatment, Patents -- Methods, Patent/copyright issue, Pharmaceuticals and cosmetics industries, Health, Science and technology
Abstract

The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 'Compositions and Methods for [...]

Published
2009

50. Advaxis Secures New Compositions and Methods Patent

Subjects
Advaxis Inc. -- Intellectual property, Biological products industry -- Intellectual property -- Methods, Biotechnology industry -- Intellectual property -- Methods, Immunotherapy -- Methods, Patents -- Methods, Patent/copyright issue, Business, Business, international, Telecommunications industry
Abstract

The United States Patent and Trademark Office has granted and issued Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 'Compositions and Methods for Enhancing Immunogenicity of [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results